Form 4: Blueprint Medicines COO Converts Equity Holdings Following Sanofi Acquisition

Blueprint Medicines Corporation's Chief Operating Officer, Christina Rossi, converted all her equity holdings, including common stock, PSUs, RSUs, and stock options, into cash and contingent value rights following the company's acquisition by Sanofi at $129.00 per share plus CVRs.

Summary

• Christina Rossi, Chief Operating Officer of Blueprint Medicines Corporation (BPMC), reported changes in her beneficial ownership of company securities.
• The changes occurred on July 17, 2025, which was the effective time of the merger where Rothko Merger Sub, Inc., a wholly-owned subsidiary of Sanofi, merged with and into Blueprint Medicines Corporation.
• Under the merger agreement, all issued and outstanding shares of Blueprint Medicines common stock were acquired for $129.00 per share in cash, plus one contractual contingent value right (CVR) per share.
• Performance-based stock units (PSUs) were deemed earned based on the greater of target and actual performance and converted into the offer consideration. Fifty percent of PSUs issued in calendar year 2025 were converted into cash-based awards subject to continued vesting.
• Restricted stock units (RSUs), both vested and unvested, were cancelled and converted into the offer consideration. Fifty percent of RSUs issued in calendar year 2025 were converted into cash-based awards subject to continued vesting.
• Stock options, both vested and unvested, became fully vested, cancelled, and converted into the cash offer price (less exercise price) and one CVR per share. Fifty percent of options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting.
• Following these transactions, Christina Rossi's direct beneficial ownership of Blueprint Medicines common stock and derivative securities is now zero.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for shareholders and the reporting person due to the acquisition at a significant premium ($129.00 per share cash plus CVRs), which fully vests and converts equity holdings. While the company ceases to be independent, the financial outcome for equity holders is favorable.

Positives

• Shareholders, including the reporting person, received a cash offer price of $129.00 per share, representing a premium for their shares.
• The inclusion of a Contingent Value Right (CVR) provides potential for additional future payments upon the achievement of certain milestones.
• All outstanding stock options, whether vested or unvested, became fully vested at the effective time of the merger, allowing holders to realize their value.
• Performance-based stock units (PSUs) were deemed earned based on the greater of target and actual performance, ensuring favorable conversion terms for the reporting person.

Negatives

• Blueprint Medicines Corporation ceases to exist as an independent publicly traded entity, becoming an indirect wholly-owned subsidiary of Sanofi.
• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future milestone achievements, which may or may not occur.

Risks

• The value of the Contingent Value Rights (CVRs) is contingent upon the achievement of certain unspecified milestones, meaning the full offer consideration may not be realized if these milestones are not met.

Future Outlook

Blueprint Medicines Corporation is now an indirect wholly-owned subsidiary of Sanofi. Its future operations and strategic direction will be determined by Sanofi, and it will no longer operate as an independent public entity.

Industry Context

This acquisition exemplifies the ongoing consolidation trend within the biopharmaceutical industry, where larger pharmaceutical companies like Sanofi acquire smaller, innovative biotech firms such as Blueprint Medicines to expand their pipeline, gain access to new technologies, or strengthen their market position in specific therapeutic areas. Such mergers often involve significant premiums and complex equity conversion mechanisms for target company executives and shareholders.

Stakeholder Impact

• Shareholders received a significant cash premium and contingent value rights for their shares, providing a favorable return on investment.
• Employees holding equity (like the reporting person) had their stock options, PSUs, and RSUs converted into cash and CVRs, with some 2025 awards subject to continued vesting, impacting their compensation structure.

Next Steps

• Integration of Blueprint Medicines Corporation into Sanofi's operations as an indirect wholly-owned subsidiary.
• Potential future payments to CVR holders upon the achievement of certain milestones.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Form 4, Insider Trading, Stock Options, RSU, PSU, Contingent Value Right, CVR, Corporate Governance, Executive Compensation